Urch Publishing: New report on global pharmaceutical Research and Development
TODAY, Urch Publishing launches a wide-ranging report on research and development (R&D) in the global pharmaceutical industry. The report, Research & Development in the Pharmaceutical Industry - Options for success, assesses the critical factors characteristic of a successful R&D organisation and the regulatory and economic environment necessary for R&D to prosper. The reportÂ’s numerous findings include: -industry players are optimistic that drug development times can be reduced: -focus on therapeutic areas to concentrate research efforts is crucial to long-term success: -generics, and now biogenerics, will continue to be a growth sector: -biotechnology companies will continue to be the source of new drugs: -careful management of alliances with drug development/biotechnology companies ensures value for money: and -companies must have appropriate systems in place to maximise R&D productivity.
(PRWEB) February 21, 2004
The report also questions the assumption that companies with high R&D spend will be the most innovative and productive. The report’s author Dr. F. Kermani, an industry analyst, believes the relationship is much more complex. “Although R&D investment by the pharma industry has been on the increase, the number of novel drugs reaching the global market has been on the decline” he said. In 2002, only 28 totally novel drugs were launched onto the world market, a number that was nearly half of the corresponding figure for 1997.
“The success of the pharmaceutical industry is based on significant investment in R&D, much of which is upfront before a company is in a position to market a product. The eventual aim of the company is to be able to finance its R&D entirely by reinvestment of profits generated through pharmaceutical sales. As the general public begin to question industry prices it is important for companies to be able to justify their commercial strategies by highlighting the investment they must make to bring a new drug successfully to market” warns Dr. Kermani.
The competitive and overcrowded nature of the pharmaceutical market means that companies are under pressure to outperform their rivals. By taking the right decision in the discovery and development of products and terminating unsuccessful drugs early, companies will be able to allocate resources more effectively and expedite development. Many companies are restructuring their R&D processes in order to optimise the selection of compounds and information flow across the discovery and development interface. An increasing number of companies have sought collaborations with other companies in order to spread the risks and costs associated with incorporating new technologies.
Research & Development in the Pharmaceutical Industry - Options for success contains information on company R&D organisational structures, the role of patent protection in ensuring a healthy research base, how companies use alliances to boost NCE output, on which therapeutic sectors the industry is concentrating, and how generic drugs companies are developing new drugs in their own right. The text is complimented by case studies from companies such as Amgen, Bioglan Pharma, Genentech, Pharsight and Scotia Holdings. The publication also analyses the regulatory regime required for efficient R&D and the impact of government incentives for R&D (such as tax breaks) on the pharmaceutical industry.
Urch Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry.
For more information contact Urch Publishing on +44 (0) 20 8690 8780 or email press@urchpublishing. com.
###
